ZAY0 Stock Chart & Stats
€0.37
-€0.01(-2.46%)
At close: 4:00 PM EDT
€0.37
-€0.01(-2.46%)
Day’s Range― - ―
52-Week Range€0.32 - €0.90
Previous CloseN/A
Volume0.00
Average Volume (3M)173.00
Market Cap
€57.77M
Enterprise Value€60.34M
Total Cash (Recent Filing)€16.60M
Total Debt (Recent Filing)€1.93M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume0
30 Day Avg. Volume173
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.69Price Target Upside356.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and meaningful equity provide a financial cushion while Zentek continues investing in development and commercialization. This reduces near-term refinancing and solvency pressure, preserving flexibility to pursue its materials technology strategy despite current operating losses.
Graphene And Nanomaterials PlatformA platform spanning multiple graphene and nanomaterial applications gives Zentek several potential routes to commercialization rather than dependence on one narrowly defined product. If development succeeds, the technology base could support expansion across industrial and technology-oriented markets.
Multiple Monetization PathwaysThe ability to monetize through product sales, intellectual-property licensing, and partner-related services creates strategic flexibility as technologies mature. Licensing can broaden reach without requiring all deployment to be handled internally, while direct sales and services offer additional commercialization avenues.
Bears Say
Very Limited Commercial TractionExtremely small and declining trailing revenue indicates that Zentek has not yet converted its technology portfolio into a substantial or consistently expanding commercial business. This weak starting base makes future growth highly dependent on successful product adoption and commercialization execution.
Persistent Unprofitable OperationsRepeated net losses and negative operating results show that the current business model has not reached sustainable profitability. The brief period of positive annual gross profit did not establish stable margins, leaving earnings power uncertain and dependent on a material improvement in revenue scale.
Ongoing Cash BurnConsistently negative operating and free cash flow means Zentek is not yet self-funding its activities and continues to consume cash while pursuing commercialization. Persistent burn can gradually reduce financial flexibility and increase reliance on future financing or successful revenue growth.
Zentek News
ZAY0 FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was €0.32 and its highest was €0.90 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is €57.77M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 40 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -€0.011 earnings per share for the quarter.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Undervalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -€0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in DE:ZAY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.69 (356.07% Upside)
€1.69 (356.07% Upside)
Insider Transactions
Bought Shares
Worth €20.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
ZAY0 Stock 12 Month Forecast
Average Price Target
€1.69
▲(356.07% Upside)
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―